Literature DB >> 25400807

Inhibition of beclin1 affects the chemotherapeutic sensitivity of osteosarcoma.

Wenxin Wu1, Wei Li2, Yong Zhou1, Chaoyue Zhang1.   

Abstract

This study was conducted to explore the role of autophagy in cisplatin-resistant osteosarcoma. Cisplatin-resistant osteosarcoma cell line (MG63/DDP) was obtained from parental MG63 by treating cisplatin with an intermittent stepwise selection protocol. The autophagy in MG63/DDP and MG63 was fully analyzed by immunofluorescence and western blot analysis. Meanwhile, the autophagy and the sensitivity to cisplatin for MG63/DDP and MG63 after inhibition of beclin1 were analyzed in vitro and in vivo. Increased autophagy was observed in cisplatin resistant MG63/DDP cells and in the cisplatin-treated MG63 and MG63/DDP cells. Meanwhile, inhibition the beclin1 significantly inhibited the formation of autophagosome and resulted in the increase in the sensitivity to cisplatin for both MG63 and MG63/DDP cells in vitro and in vivo. In conclusion, autophagy is implicated in the cisplatin resistant osteosarcoma, and inhibition of beclin1 could be a target for improving osteosarcoma therapy.

Entities:  

Keywords:  Cisplatin; MG63; autophagy; beclin1; osteosarcoma

Mesh:

Substances:

Year:  2014        PMID: 25400807      PMCID: PMC4230152     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

1.  Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.

Authors:  Jun Huang; Ke Liu; Yan Yu; Min Xie; Rui Kang; Philip Vernon; Lizhi Cao; Daolin Tang; Jiangdong Ni
Journal:  Autophagy       Date:  2012-02-01       Impact factor: 16.016

2.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  Methods in mammalian autophagy research.

Authors:  Noboru Mizushima; Tamotsu Yoshimori; Beth Levine
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

4.  The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.

Authors:  Jun Hayakawa; Chantal Depatie; Masahide Ohmichi; Dan Mercola
Journal:  J Biol Chem       Date:  2003-03-27       Impact factor: 5.157

Review 5.  Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.

Authors:  James C Wittig; Jacob Bickels; Dennis Priebat; James Jelinek; Kristen Kellar-Graney; Barr Shmookler; Martin M Malawer
Journal:  Am Fam Physician       Date:  2002-03-15       Impact factor: 3.292

6.  Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG.

Authors:  Eisuke Itakura; Chieko Kishi; Kinji Inoue; Noboru Mizushima
Journal:  Mol Biol Cell       Date:  2008-10-08       Impact factor: 4.138

7.  Unfolded protein response suppresses cisplatin-induced apoptosis via autophagy regulation in human hepatocellular carcinoma cells.

Authors:  R Chen; R Y Dai; C Y Duan; Y P Liu; S K Chen; D M Yan; C N Chen; M Wei; H Li
Journal:  Folia Biol (Praha)       Date:  2011       Impact factor: 0.906

Review 8.  Modulation of translation and induction of autophagy by bacterial exoproducts.

Authors:  Gisela von Hoven; Nicole Kloft; Claudia Neukirch; Sabrina Ebinger; Wiesia Bobkiewicz; Silvia Weis; Klaus Boller; Kim D Janda; Matthias Husmann
Journal:  Med Microbiol Immunol       Date:  2012-09-19       Impact factor: 3.402

9.  Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells.

Authors:  Akitomi Shirato; Tadahiko Kikugawa; Noriyoshi Miura; Nozomu Tanji; Nobuaki Takemori; Shigeki Higashiyama; Masayoshi Yokoyama
Journal:  Oncol Lett       Date:  2013-12-19       Impact factor: 2.967

10.  TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.

Authors:  W Xu; S Wang; Q Chen; Y Zhang; P Ni; X Wu; J Zhang; F Qiang; A Li; O D Røe; S Xu; M Wang; R Zhang; J Zhou
Journal:  Cell Death Dis       Date:  2014-02-13       Impact factor: 8.469

View more
  10 in total

1.  Oncolytic adenovirus Ad11 enhances the chemotherapy effect of cisplatin on osteosarcoma cells by inhibiting autophagy.

Authors:  Bin Zhang; Yan Zhang; Rongzhen Li; Jiazhen Li; Xinchang Lu; Yi Zhang
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

2.  Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.

Authors:  Jinghua Wu; Jiapei Guo; Qing Cao; Yi Wang; Junmao Chen; Zhigang Wang; Zhiyong Yuan
Journal:  Oncol Lett       Date:  2016-12-08       Impact factor: 2.967

3.  The metastasis suppressor gene KISS-1 regulates osteosarcoma apoptosis and autophagy processes.

Authors:  Yiran Yin; Lian Tang; Lei Shi
Journal:  Mol Med Rep       Date:  2017-01-11       Impact factor: 2.952

4.  Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.

Authors:  Xilong Sun; Qiang Wei; Jie Cheng; Yanzhu Bian; Congna Tian; Yujing Hu; Huijie Li
Journal:  Hum Cell       Date:  2017-03-22       Impact factor: 4.174

5.  Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity through inhibition of autophagy.

Authors:  Zili Wang; Rongzhen He; Hansong Xia; Yu Wei; Song Wu
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

6.  MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma.

Authors:  Ren Chen; Xiaohai Li; Bin He; Wei Hu
Journal:  Mol Med Rep       Date:  2017-01-26       Impact factor: 2.952

Review 7.  Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma.

Authors:  Yu-Xin Liao; Hai-Yang Yu; Ji-Yang Lv; Yan-Rong Cai; Fei Liu; Zhi-Min He; Shi-Sheng He
Journal:  Int J Oncol       Date:  2019-10-18       Impact factor: 5.650

8.  Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells.

Authors:  Heena Saini; Harshita Sharma; Sudeshna Mukherjee; Shibasish Chowdhury; Rajdeep Chowdhury
Journal:  Cancer Cell Int       Date:  2021-01-14       Impact factor: 5.722

9.  Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Safaa A Ibrahim; Valerie Riehl; Manoranjan Sahoo; James Dolan; Kyle W Meinke; Michael R Pins; Kenneth D Beaman
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

Review 10.  Molecular Mechanisms Underlying Autophagy-Mediated Treatment Resistance in Cancer.

Authors:  Cally J Ho; Sharon M Gorski
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.